StratDeck

Two stocks in Healthcare

Convatec Group vs GSK: profit, growth, debt and price compared

Convatec Group is stronger on 4 of 7 figures: sales growth, debt, analysts' view and price trend. GSK is stronger on 3: profit margin, price for its expected profit and dividend.

Figures as of 18 November 2026Yahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Convatec Group and GSK side by side
Convatec GroupCTEC.LGSKGSK.L
Net margin5.0%Stronger: 13.0%
Revenue growth, past yearStronger: +4.40%+4.00%
Debt to equityStronger: 121.8%129.6%
Forward P/E15.7×Stronger: 9.9×
Dividend yield2.25%Stronger: 3.64%
AnalystsStronger: Strong buy · 19Hold · 21
From its 200-day averageStronger: +17.9%−0.8%

Share price over the past year

  • Convatec Group+15.1%
  • GSK+5.5%

20 Nov 202518 Nov 2026

Convatec Group or GSK: which is stronger?

  • GSK.L

    Which is more profitable?

    GSK keeps more of each sale as profit: 13.0% against 5.0%.

  • CTEC.L

    Which is growing its sales faster?

    Convatec Group is growing its sales faster: +4.40% over the past year, against +4.00%.

  • CTEC.L

    Which has borrowed less?

    Convatec Group has borrowed less: its debt is 121.8% of what its shareholders own, against 129.6% for GSK.

  • GSK.L

    Which costs less for the profit it is expected to make?

    GSK costs less for the profit it is expected to make: 9.9× its forward earnings, against 15.7×.

  • GSK.L

    Which pays more in dividends?

    GSK pays more back in dividends for what a share costs: 3.64% a year, against 2.25%.

  • CTEC.L

    Which do analysts rate higher?

    Analysts are warmer on Convatec Group: Strong buy, against Hold for GSK.

  • CTEC.L

    Which is in the stronger price trend?

    Convatec Group's price is in the stronger trend: 17.9% above its 200-day average, against 0.8% below.

What each company does

CTEC.LConvatec Group

Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally.

Reports results on 23 February 2027

GSK.LGSK

GSK plc, together with its subsidiaries, researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

Reports results on 3 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every UK healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.